Literature DB >> 403765

The effect of contraceptive steroids on hypothalamic-pituitary function.

D R Mishell, O A Kletzky, P F Brenner, S Roy, J Nicoloff.   

Abstract

A study was performed to obtain additional information about the effects of oral contraceptives on pituitary function. A sequential pituitary stimulation test (SST) was used to study normal control women who then received either a combination pill with 50 mug of ethinyl estradiol or an injectable or oral progestin for three weeks, after which the test was repeated. The same test was also performed on five long-term oral contraceptive users. The SST consists of measurement of growth hormone (GH), thyroid-stimulating hormone (TSH), prolactin (PRL), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) at frequent intervals after stimulation by hypoglycemia, thyrotropin-releasing hormone, and gonadotropin-releasing hormone. GH and TSH release following stimulation were unaffected by the use of contraceptive steroids, while PRL release was increased by both the combination pill and the progestin alone. LH and FSH release was decreased in the three short-term and most of the long-term users of the combination pills but was not decreased in two of the long-term users as well as in those receiving the progestin alone. These results indicate that the combination oral contraceptives have a direct effect upon the pituitary gland, causing an increase in prolactin release and a decrease in gonadotropin release. This effect varies among individuals receiving the same formulation and may be related to the development of syndrome of postpill amenorrhea-galactorrhea.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Endocrine System; Ethinyl Estradiol--administraction and dosage; Ethinyl Estradiol--side effects; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hormones; Injectables; Luteinizing Hormone--analysis; Medroxyprogesterone Acetate--administraction and dosage; Medroxyprogesterone Acetate--side effects; Mestranol; Norethindrone; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Pituitary Hormones--analysis; Prolactin--analysis; Research Methodology

Mesh:

Substances:

Year:  1977        PMID: 403765     DOI: 10.1016/0002-9378(77)90295-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

1.  Cytological study on the anterior pituitary of beagle bitches treated subcutaneously with progesterone for 13 weeks.

Authors:  M A Attia; I Zayed
Journal:  Arch Toxicol       Date:  1979-06-08       Impact factor: 5.153

2.  Improved Delivery Through Biological Membranes. XXIV. Synthesis, in Vitro Studies, and in Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems.

Authors:  M E Brewster; K S Estes; N Bodor
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

Review 3.  Injectable contraception with depot medroxyprogesterone acetate. Current status.

Authors:  Andrew M Kaunitz; Allan Rosenfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Symposium on Adolescent Gynecology and Endocrinology. Part II: Secondary amenorrhea, hirsutism in adolescents and the clinical consequences of stilbestrol exposure in utero. The clinical consequences of stilbestrol exposure in utero.

Authors:  R J Kurman
Journal:  West J Med       Date:  1979-12

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

7.  A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.

Authors:  H Olsson; A Borg; S B Ewers; M Fernö; T Möller; J Ranstam
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

8.  Hormonal contraceptive use diminishes salivary cortisol response to psychosocial stress and naltrexone in healthy women.

Authors:  Daniel J O Roche; Andrea C King; Andrew J Cohoon; William R Lovallo
Journal:  Pharmacol Biochem Behav       Date:  2013-05-12       Impact factor: 3.533

9.  The effect of exercise duration and mode on the growth hormone responses in young women on oral contraceptives.

Authors:  Lynn M Sauro; Jill A Kanaley
Journal:  Eur J Appl Physiol       Date:  2003-06-14       Impact factor: 3.078

Review 10.  Contraceptive steroids and the mammary gland: is there a hazard?--Insights from animal studies.

Authors:  G R Rutteman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.